



(11) **EP 1 214 088 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**22.04.2009 Bulletin 2009/17**

(21) Application number: **00928851.5**

(22) Date of filing: **04.05.2000**

(51) Int Cl.:  
**A61K 39/00** (2006.01) **A61K 39/02** (2006.01)  
**A61K 39/04** (2006.01) **A61K 38/00** (2006.01)  
**C07H 21/02** (2006.01) **C07H 21/04** (2006.01)  
**C07K 1/00** (2006.01) **C12P 21/06** (2006.01)  
**C12N 1/00** (2006.01) **C12N 1/12** (2006.01)

(86) International application number:  
**PCT/US2000/012257**

(87) International publication number:  
**WO 2000/066157 (09.11.2000 Gazette 2000/45)**

(54) **PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS DIAGNOSTIC REAGENTS AND VACCINES**

DURCH MYCOBACTERIUM TUBERCULOSIS UND NICHT DURCH BCG EXPRIMIERTE PROTEINE UND IHRE VERWENDUNG ALS DIAGNOSTISCHE REAGENZIEN UND IMPFSTOFFE

PROTEINES EXPRIMEES PAR MYCOBACTERIUM TUBERCULOSIS ET NON PAR BCG ET EMPLOYEES EN TANT QUE VACCINS ET REACTIFS DE DIAGNOSTIC

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE**

(30) Priority: **04.05.1999 US 132505 P**

(43) Date of publication of application:  
**19.06.2002 Bulletin 2002/25**

(73) Proprietor: **The University of Medicine and Dentistry of New Jersey Newark NJ 07107-3001 (US)**

(72) Inventor: **GENNARO, Maria, L. New York, NY 10023 (US)**

(74) Representative: **Bizley, Richard Edward et al HLBBshaw Merlin House Falconry Court Baker's Lane Epping, Essex CM16 5DQ (GB)**

(56) References cited:  
**WO-A1-98/44119 WO-A2-98/16645**

- **DATABASE EBI [Online] COLE S T ET AL: "Mycobacterium tuberculosis H37Rv complete genome; segment 160/162" retrieved from EMBL Database accession no. AL022120 XP002218539 & COLE S T ET AL: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence" NATURE, vol. 393, 11 June 1998 (1998-06-11), pages 537-544, XP002087941**
- **MAHAIRAS GREGORY G ET AL: "Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis." JOURNAL OF BACTERIOLOGY, vol. 178, no. 5, 1996, pages 1274-1282, XP000647583 ISSN: 0021-9193**
- **BERTHET F-X ET AL: "A Mycobacterium Tuberculosis Operon Encoding ESAT-6 and a Novel Low-Molecularmass Culture Filtrate Protein (CFP-10)" MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 144, 1998, pages 3195-3203, XP002901305 ISSN: 1350-0872**
- **COLANGELI R. ET AL.: 'MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs' INFECTION AND IMMUNITY, vol. 68, no. 2, February 2000, pages 990 - 993, XP002931223**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 214 088 B1**

- LYASHCHENKO K. ET AL.: 'Use of Mycobacterium tuberculosis complex-specific antigen cocktails for a skin test specific for tuberculosis' INFECTION AND IMMUNITY, vol. 66, no. 8, August 1998, pages 3606 - 3610, XP002932118
- MANCA C. ET AL.: 'MTC28, a novel 28-kilodalton proline-rich secreted antigen specific for the mycobacterium tuberculosis complex' INFECTION AND IMMUNITY, vol. 65, no. 12, December 1997, pages 4951 - 4957, XP002931221
- MANCA C. ET AL.: 'Molecular cloning, purification and serological characterization of MPT63, a novel antigen secreted by mycobacterium tuberculosis' INFECTION AND IMMUNITY, vol. 65, no. 1, January 1997, pages 16 - 23, XP002931222

## Description

**[0001]** The invention is in the field of tuberculosis and, specifically, reagents useful for generating immune responses to *Mycobacterium tuberculosis* and for diagnosing infection and disease in a subject that has been exposed to *M. tuberculosis*.

### Background of the Invention

**[0002]** Tuberculosis infection continues to be a worldwide health problem. This situation has recently been greatly exacerbated by the emergence of multi-drug resistant strains of *M. tuberculosis* and the international AIDS epidemic. It has thus become increasingly important that effective vaccines against and reliable diagnostic reagents for *M. tuberculosis* be produced.

### Summary of the Invention

**[0003]** The invention is based on the inventor's discovery that a polypeptide encoded by an open reading frame (ORF) in the genome of *M. tuberculosis* that is absent from the genome of the Bacille Calmette Guerin (BCG) strain of *M. bovis* elicited a delayed-type hypersensitivity response in animals infected with *M. tuberculosis* but not in animals sensitized with BCG. Thus proteins encoded by ORFs present in the genome of *M. tuberculosis* but absent from the genome of BCG represent reagents that are useful in discriminating between *M. tuberculosis* and BCG and, in particular, for diagnostic methods (e.g., skin tests and *in vitro* assays for *M. tuberculosis*-specific antibodies and lymphocyte responsiveness) which discriminate between exposure of a subject to *M. tuberculosis* and vaccination with BCG. Thus, the present invention relates to *in vitro* methods of diagnosis which discriminate between exposure of a subject to *M. tuberculosis* and exposure of a subject to BCG. In one embodiment, the method comprises testing a population of cells from a subject for the presence of CD4 T Lymphocytes that respond to MTBN4, as depicted in Figure 1, wherein the presence of CD4 T lymphocytes that respond to MTBN4 indicates that the subject has been exposed to *M. tuberculosis* and not to BCG without exposure to *M. tuberculosis*.

**[0004]** In an alternative embodiment, the method comprises testing a subject for the presence of B lymphocytes which produce antibodies that bind to MTBN4, the testing being carried out on a bodily fluid from the subject, wherein the presence in the subject of B lymphocytes that produce antibodies that bind to MTBN4 indicates that the subject has been infected by exposure to *M. tuberculosis* and not to BCG without exposure to *M. tuberculosis*.

**[0005]** The invention also features vectors comprising the DNA molecules encoding polypeptides MTBN4 and compositions comprising these polypeptides. A variety of diagnostic methodologies utilizing the foregoing are also provided.

**[0006]** In one embodiment, the invention features a vector comprising: (a) the DNA molecule encoding the polypeptide MTBN4, as depicted in Figure 1, and (b) transcriptional and translational regulatory sequences operationally linked to said DNA sequence, said regulatory sequences allowing for expression of the polypeptide encoded by said DNA sequence in a cell, for use as a diagnostic. The encoded polypeptide has *Mycobacterium tuberculosis* specific antigenic and immunogenic properties. Also defined herein is an isolated portion of the above DNA molecule. The portion of the DNA molecule encodes a segment of the polypeptide shorter than the full-length polypeptide, and the segment has *Mycobacterium tuberculosis* specific antigenic and immunogenic properties. Cells which can be used to express the polypeptide encoded within the vector include both eukaryotic and prokaryotic cells.

**[0007]** The above vectors can be incorporated into compositions comprising a pharmaceutically acceptable diluent or filler. Other compositions which can be used contain at least two (eg three, four, five, six, seven, eight, nine, ten, twelve, fifteen, or twenty) DNA sequences, each encoding a polypeptide of the *Mycobacterium tuberculosis* complex or a functional segment thereof, with the DNA sequences being operationally linked to transcriptional and translational regulatory sequences which allow for expression of each of the polypeptides in a cell of a vertebrate. In such compositions, at least one (eg two, three, four, five, six, seven or eight) of the DNA sequences is a DNA molecule encoding the polypeptide MTBN4, as depicted in Figure 1. The encoded polypeptides will preferably be those not encoded by the genome of cells of the BCG strain of *M. bovis*.

**[0008]** The specification describes a polypeptide comprising the MTBN4 sequence as depicted in Fig. 1. The invention also features a composition comprising said polypeptide and at least one other polypeptide of the *Mycobacterium tuberculosis* complex, not being encoded by the genome of the cells of the BCG strain of *Mycobacterium bovis*, for use as a diagnostic. The at least one other polypeptide can be selected from the group consisting of MTBN1, MTBN2, MTBN3, MTBN4, MTBN5, MTBN6, MTBN7 and MTBN8 as depicted in Figure 1, or polypeptides with amino acid sequences identical thereto with conservative substitutions. The polypeptide has *Mycobacterium tuberculosis* specific antigenic and immunogenic properties. Also defined herein is an isolated segment of the above polypeptides, the segment being shorter than the full-length polypeptide and having *Mycobacterium tuberculosis* specific antigenic and immunogenic properties. The polypeptides and composition of the invention can be used with a pharmaceutically acceptable diluent or filler. Compositions of the invention can also contain at least two (eg three, four, five, six, seven, eight, nine, ten, twelve, fifteen, or twenty) polypeptides of the *Mycobacterium tuberculosis* complex, or functional segments thereof, with at least one of the at least two (eg two, three, four, five, six, seven, or eight)

polypeptides comprising the MTBN4 sequence, as depicted in figure 1. The polypeptides will preferably be those not encoded by the genome of cells of the BCG strain of *M. bovis*.

**[0009]** The invention also features polypeptides, compositions and vectors as defined above, for use as diagnostics. Although not part of the invention as such, methods can be employed involving (a) administration of one of the above polypeptide compositions to a subject suspected of having or being susceptible to *Mycobacterium tuberculosis* infection; and (b) detecting an immune response in the subject to the composition, as an indication that the subject has or is susceptible to *Mycobacterium tuberculosis* infection. An example of such a method is a skin test in which the test substance (e.g., compositions containing one or more of MTBN1 - MTBN8) is injected intradermally into the subject and in which a skin delayed-type hypersensitivity response is tested for.

**[0010]** In a further aspect, the invention relates to an *in vitro* method of diagnosis comprising (a) contacting CD4 T lymphocytes with antigen presenting cells (APC) in the presence of a polypeptide comprising the MTBN4 sequence, as depicted in Figure 1, wherein said CD4 T lymphocytes are from a population of cells from a subject, and wherein said APC express at least one major histocompatibility complex (MHC) class II molecule expressed by said subject; and (b) determining the ability of said CD4 T lymphocytes to respond to said polypeptide, as an indication that said subject has or is susceptible to *Mycobacterium tuberculosis* infection. Another *in vitro* diagnostic method of the invention involves: (a) contacting a polypeptide comprising the MTBN4 sequence, as depicted in Figure 1 with a bodily fluid of a subject; (b) detecting the presence of binding of antibody to said polypeptide as indication that said subject has or is susceptible to *Mycobacterium tuberculosis* infection.

**[0011]** In the above *in vitro* diagnostic methods of the invention, the polypeptide comprising MTBN4 may be present within a composition comprising at least one other polypeptide as defined above.

**[0012]** Also encompassed by the invention is the use of a polypeptide composition or vector as defined herein, for the manufacture of a medicament for diagnosing exposure of a subject to *Mycobacterium tuberculosis*.

**[0013]** As used herein, an "isolated DNA molecule" is a DNA which is one or both of: not immediately contiguous with one or both of the coding sequences with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the DNA is derived; or which is substantially free of DNA sequence with which it occurs in the organism from which the DNA is derived. The term includes, for example, a recombinant DNA which incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic fragment produced by PCR or restriction endonuclease treatment) inde-

pendent of other DNA sequences. Isolated DNA also includes a recombinant DNA which is part of a hybrid DNA encoding additional *M. tuberculosis* polypeptide sequences.

**[0014]** "DNA molecules" include cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. Where single-stranded, the DNA molecule may be a sense strand or an antisense strand.

**[0015]** An "isolated polypeptide" of the invention is a polypeptide which either has no naturally-occurring counterpart, or has been separated or purified from components which naturally accompany it, e.g., in *M. tuberculosis* bacteria. Typically, the polypeptide is considered "isolated" when it is at least 70%, by dry weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, a preparation of a polypeptide of the invention is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, the peptide of the invention. Since a polypeptide that is chemically synthesized is, by its nature, separated from the components that naturally accompany it, the synthetic polypeptide is "isolated."

**[0016]** An isolated polypeptide of the invention can be obtained, for example, by extraction from a natural source (e.g., *M. tuberculosis* bacteria); by expression of a recombinant nucleic acid encoding the polypeptide; or by chemical synthesis. A polypeptide that is produced in a cellular system different from the source from which it naturally originates is "isolated," because it will be separated from components which naturally accompany it. The extent of isolation or purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

**[0017]** The polypeptides may contain a primary amino acid sequence that has been modified from those disclosed herein. Preferably these modifications consist of conservative amino acid substitutions. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.

**[0018]** The terms "protein" and "polypeptide" are used herein to describe any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation). Thus, the term "*Mycobacterium tuberculosis* polypeptide" includes full-length, naturally occurring *Mycobacterium tuberculosis* protein, as well a recombinantly or synthetically produced polypeptide that corresponds to a full-length naturally occurring *Mycobacterium tuberculosis* protein or to particular domains or portions of a naturally occurring protein. The term also encompasses a mature *Mycobacterium tuberculosis* polypeptide which has an added amino-terminal methionine (useful for expression in prokaryotic cells) or any short amino acid sequences useful for protein purification by affinity chromatography, e.g., polyhistidine for purification by metal chelate chromatography.

**[0019]** As used herein, "immunogenic" means capable of activating a primary or memory immune response. Immune responses include responses of CD4+ and CD8+ T lymphocytes and B-lymphocytes. In the case of T lymphocytes, such responses can be proliferative, and/or cytokine (e.g., interleukin(IL)-2, IL-3, IL-4, IL-5, IL-6, IL-12, IL-13, IL-15, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), or interferon- $\gamma$  (IFN- $\gamma$ ))-producing, or they can result in generation of cytotoxic T-lymphocytes (CTL). B-lymphocyte responses can be those resulting in antibody production by the responding B lymphocytes.

**[0020]** As used herein, "antigenic" means capable of being recognized by either antibody molecules or antigen-specific T cell receptors (TCR) on activated effector T cells (e.g., cytokine-producing T cells or CTL).

**[0021]** Thus, polypeptides that have "*Mycobacterium tuberculosis* specific antigenic properties" are polypeptides that: (a) can be recognized by and bind to antibodies elicited in response to *Mycobacterium tuberculosis* organisms or wild-type *Mycobacterium tuberculosis* molecules (e.g., polypeptides); or (b) contain subsequences which, subsequent to processing of the polypeptide by appropriate antigen presenting cells (APC) and bound to appropriate major histocompatibility complex (MHC) molecules, are recognized by and bind to TCR on effector T cells elicited in response to *Mycobacterium tuberculosis* organisms or wild-type *Mycobacterium tuberculosis* molecules (e.g., polypeptides).

**[0022]** As used herein, polypeptides that have "*Mycobacterium tuberculosis* specific immunogenic properties" are polypeptides that: (a) can elicit the production of antibodies that recognize and bind to *Mycobacterium tuberculosis* organisms or wild-type *Mycobacterium tuberculosis* molecules (e.g., polypeptides); or (b) contain subsequences which, subsequent to processing of the polypeptide by appropriate antigen presenting cells (APC) and bound to appropriate major histocompatibility complex (MHC) molecules on the surface of the APC, activate T cells with TCR that recognize and bind to peptide fragments derived by processing by APC of *Mycobacterium tuberculosis* organisms or wild-type *Mycobacterium tuberculosis* molecules (e.g., polypeptides) and bound to MHC molecules on the surface of the APC. The immune responses elicited in response to the immunogenic polypeptides are preferably protective. As used herein, "protective" means preventing establishment of an infection or onset of a disease or lessening the severity of a disease existing in a subject. "Preventing" can include delaying onset, as well as partially or completely blocking progress of the disease.

**[0023]** As used herein, a "functional segment of a *Mycobacterium tuberculosis* polypeptide" is a segment of the polypeptide that has *Mycobacterium tuberculosis* specific antigenic and immunogenic properties.

**[0024]** Where a polypeptide, functional segment of a polypeptide, or a mixture of polypeptides and/or functional segments have been administered (e.g., by intradermal injection) to a subject for the purpose of testing for

a *M. tuberculosis* infection or susceptibility to such an infection, "detecting an immune response" means examining the subject for signs of an immunological reaction to the administered material, e.g., reddening or swelling of the skin at the site of an intradermal injection. Where the subject has antibodies to the administered material, the response will generally be rapid, e.g., 1 minute to 24 hours. On the other hand, a memory or activated T cell reaction of pre-immunized T lymphocytes in the subject is generally slower, appearing only after 24 hours and being maximal at 24-96 hours.

**[0025]** As used herein, a "subject" can be a human subject or a non-human mammal such as a non-human primate, a horse, a bovine animal, a pig, a sheep, a goat, a dog, a cat, a rabbit, a guinea pig, a hamster, a rat, or a mouse.

**[0026]** Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. Unless otherwise indicated, these materials and methods are illustrative only and are not intended to be limiting. All publications, patent applications, patents and other references mentioned herein are illustrative only and not intended to be limiting.

**[0027]** Other features and advantages of the invention, e.g., methods of diagnosing *M. tuberculosis* infection, will be apparent from the following description, from the drawings and from the claims.

### Brief Description of the Drawings

#### **[0028]**

Figure 1 is a depiction of the amino acid sequences of *M. tuberculosis* polypeptides MTBN1-MTBN8.

Figure 2 is a depiction of the nucleotide sequences of the coding regions (mtbn1-mtbn8) encoding MTBN1-MTBN8.

Figure 3 is a bar graph showing the delayed-type hypersensitivity responses induced by intradermal injection of 3 different test reagents in female guinea pigs that had been either infected with *M. tuberculosis* cells or sensitized with BCG or *M. avium* cells.

### Detailed Description

**[0029]** The genome of *M. tuberculosis* [Cole et al. (1998) Nature 393:537-544] contains open reading frames (ORFs) that have been deleted from the avirulent BCG strain. The polypeptides encoded by these ORFs are designated herein "*M. tuberculosis* BCG Negative" polypeptides ("MTBN") and the ORFs are designated "mtbn." The invention is based on the discovery that a

MTBN polypeptide (MTBN4) elicited a skin response in animals infected with *M. tuberculosis*, but not in animals sensitized to either BCG or *M. avium*, a non-*M. tuberculosis*-complex strain of mycobacteria (see Example 1 below). These findings indicate that MTBN (e.g., MTBN1-MTBN8) can be used in diagnostic tests that discriminate infection of a subject by *M. tuberculosis* from exposure to both mycobacteria other than the *M. tuberculosis*-complex and BCG. The *M. tuberculosis*-complex includes *M. tuberculosis*, *M. bovis*, *M. microti*, and *M. africanum*. Thus they can be used to discriminate subjects exposed to *M. tuberculosis*, and thus potentially having or being in danger of having tuberculosis, from subjects that have been vaccinated with BCG, the most widely used tuberculosis vaccine. Diagnostic assays that are capable of such discrimination represent a major advance that will greatly reduce wasted effort and consequent costs resulting from further diagnostic tests and/or therapeutic procedures in subjects that have given positive results in less discriminatory diagnostic tests. Furthermore, the results in Example 1 show that MTBN4, as expressed by whole viable *M. tuberculosis* organisms, is capable of inducing a strong immune response in subjects infected with the organisms and thus has the potential to be a vaccine.

**[0030]** The MTBN polypeptides defined herein include, for example, polypeptides encoded within the RD1, RD2, and RD3 regions of the *M. tuberculosis* genome [Mahairas et al. (1996) J. Bacteriol. 178:1274-1282]. Of particular interest are polypeptides encoded by ORFs within the RD1 regions of the *M. tuberculosis* genome. The amino acid sequences of MTBN1-MTBN8 are shown in Fig. 1 and the nucleotide sequences of mtbn1-mtbn8 are shown in Fig. 2.

**[0031]** Described herein are: (a) isolated DNA molecules containing mtbn sequences (e.g., mtbn1-mtbn8) encoding MTBN polypeptides (e.g., MTBN1-MTBN8) and isolated portions of such DNA molecules that encode polypeptide segments having antigenic and immunogenic properties (i.e., functional segments); (b) the MTBN polypeptides themselves (e.g., MTBN1-MTBN8) and functional segments of them; (c) antibodies (including antigen binding fragments, e.g., F(ab')<sub>2</sub>, Fab, Fv, and single chain Fv fragments of such antibodies) that bind to the MTBN polypeptides (e.g., MTBN1-MTBN8) and functional segments; (d) nucleic acid molecules (e.g., vectors) containing and capable of expressing one or more of the mtbn (e.g., mtbn1-mtbn8) sequences and portions of DNA molecules; (e) cells (e.g., bacterial, yeast, insect, or mammalian cells) transformed by such vectors; (f) compositions containing vectors encoding one or more *M. tuberculosis* polypeptides (or functional segments) including both the MTBN (e.g., MTBN1-MTBN8) polypeptides (or functional segments thereof) and previously described *M. tuberculosis* polypeptides such as ESAT-6, 14 kDa antigen, MPT63, 19 kDa antigen, MPT64, MPT51, MTC28, 38 kDa antigen, 45/47 kDa antigen, MPB70, Ag85 complex, MPT53, and KatG (see

also U.S. application no. 08/796,792); (g) compositions containing one or more *M. tuberculosis* polypeptides (or functional segments), including both the polypeptides of the invention and previously described *M. tuberculosis* polypeptides such as those described above; (h) compositions containing one or more of the antibodies described in (c); (i) methods of diagnosis involving either (1) administration (e.g., intradermal injection) of any of the above polypeptide compositions to a subject suspected of having or being susceptible to *M. tuberculosis* infection, (2) *in vitro* testing of lymphocytes (B-lymphocytes, CD4 T lymphocytes, and CD8 T lymphocytes) from such a subject for responsiveness (e.g., by measuring cell proliferation, antibody production, cytokine production, or CTL activity) to any of the above polypeptide compositions, (3) testing of a bodily fluid (e.g., blood, saliva, plasma, serum, urine, or semen or a lavage such as a bronchoalveolar lavage, a vaginal lavage, or lower gastrointestinal lavage) for antibodies to the MTBN polypeptides (e.g., MTBN1-MTBN8) or functional segments thereof, or the above-described polypeptide compositions; (4) testing of a bodily fluid (e.g., as above) for the presence of *M. tuberculosis*, MTBN (e.g., MTBN1-MTBN8) polypeptides or functional segments thereof, or the above-described polypeptide compositions in assays using the antibodies described in (c); and (5) testing of a tissue (e.g., lung or bronchial tissue) or a body fluid (e.g., as above) for the presence of nucleic acid molecules (e.g., DNA or RNA) encoding MTBN polypeptides (e.g., MTBN1-MTBN8) (or portions of such a nucleic acid molecules) using nucleic acid probes or primers having nucleotide sequences of the nucleic molecules, portions of the nucleic molecules, or the complements of such molecules; and (j) methods of vaccination involving administration to a subject of the compositions of either (f), (g), (h) or a combination of any two or even all 3 compositions.

**[0032]** With respect to diagnosis, purified MTBN proteins, functional segments of such proteins, or mixtures of proteins and/or the functional fragments have the above-described advantages of discriminating infection by *M. tuberculosis* from either infection by other bacteria, and in particular, non-pathogenic mycobacteria, or from exposure (by, for example, vaccination) to BCG. Furthermore, compositions containing the proteins, functional segments of the proteins, or mixtures of the proteins and/or the functional segments allows for improved quality control since "batch-to-batch" variability is greatly reduced in comparison to complex mixtures such as purified protein derivative (PPD) of tuberculin.

**[0033]** The use of the above-described polypeptide and nucleic acid reagents for vaccination also provides for highly specific and effective immunization. Since the virulent *M. tuberculosis* polypeptides encoded by genes absent from avirulent BCG are likely to be mediators of virulence, immunity directed to them can be especially potent in terms of protective capacity. Where vaccination is performed with nucleic acids both *in vivo* and *ex vivo*

methods can be used. *In vivo* methods involve administration of the nucleic acids themselves to the subject and *ex vivo* methods involve obtaining cells (e.g., bone marrow cells or fibroblasts) from the subject, transducing the cells with the nucleic acids, preferably selecting or enriching for successfully transduced cells, and administering the transduced cells to the subject. Alternatively, the cells that are transduced and administered to the subject can be derived from another subject. Methods of vaccination and diagnosis are described in greater detail in U.S. application no. 08/796,792.

[0034] The following example is meant to illustrate, not limit the invention.

#### **Example 1. MPBN4 Elicits a Specific skin Reaction in Guinea Pigs Infected with *M. tuberculosis***

[0035] Four groups of outbred female guinea pigs (18 per group) were used to test the usefulness of the MTBN4 polypeptide as a *M. tuberculosis*-specific diagnostic reagents. The four groups were treated as follows.

Group 1 animals were infected by aerosol with approximately 100 *M. tuberculosis strain H37Rv* cells.

Group 2 animals were sensitized intradermally with 10<sup>6</sup> live *M. bovis* BCG Japanese cells.

Group 3 animals were sensitized intradermally with 10<sup>6</sup> live *M. avium* cells.

Group 4 animals were mock-sensitized by intradermal injection with saline.

[0036] Seven weeks after infection or sensitization, the animals were injected intradermally with 1 µg of PPD (6 animals from each group), 2 µg of purified recombinant MPT64 (6 animals from each group), or 2 µg of MTBN4 (6 animals from each group). The diameter of the resulting erythema was measured 24 hours later. Data are expressed as mean diameter of erythema (in mm) and standard deviations are indicated (Fig. 3).

[0037] No erythema was detected in the group 4 animals with any test substance and thus no data are shown for this group. On the other hand, group 1 animals (solid bars) showed a significant response with all three test substance. Group 2 animals (open bars) showed a significant response to PPD and MPT64 but not MTBN4. Group 3 animals showed a significant response to PPD only (hatched bars).

[0038] Thus, PPD which contains antigenic/immunogenic molecules common to the *M. tuberculosis*-complex as well as other mycobacterial strains, gave the least discriminatory results in that it induced responses in animals infected with or sensitized to mycobacteria of the *M. tuberculosis*-complex (*M. tuberculosis* and BCG) as well as another non-pathogenic mycobacterium (*M. avium*). While MPT64, which is encoded and expressed by both *M. tuberculosis* and BCG, did not elicit a response in animals infected with *M. avium*, it did elicit responses in both the *M. tuberculosis* infected and the BCG sensitized animals. Finally, MTBN4 elicited a response in only the *M. tuberculosis* animals. Thus it induced the most

specific response and, most importantly, allowed for discrimination between animals infected with *M. tuberculosis* and those sensitized to BCG.

[0039] Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made. Accordingly, the invention is limited only by the following claims.

#### **Claims**

1. An *in vitro* method of diagnosis which discriminates between exposure of a subject to *Mycobacterium tuberculosis* (*M. tuberculosis*) and exposure of a subject to the Bacille Calmette Guerin strain of *Mycobacterium bovis* (BCG), the method comprising testing a population of cells from a subject for the presence of CD4 T lymphocytes that respond to MTBN4, as depicted in Figure 1, wherein the presence of CD4 T lymphocytes that respond to MTBN4 indicates that the subject has been exposed to *M. tuberculosis* and not to BCG without exposure to *M. tuberculosis*.
2. An *in vitro* method of diagnosis which discriminates between exposure of a subject to *M. tuberculosis* and exposure of a subject to BCG, the method comprising: testing a subject for the presence of B lymphocytes which produce antibodies that bind to MTBN4, the testing being carried out on a bodily fluid from the subject, wherein the presence in the subject of B lymphocytes that produce antibodies that bind to MTBN4 indicates that the subject has been infected by exposed to *M. tuberculosis* and not to BCG without exposure to *M. tuberculosis*.
3. A method as claimed in claim 1 or claim 2, wherein said polypeptide is present within a composition comprising at least one other polypeptide of the *M. tuberculosis* complex, said at least one other polypeptide not being encoded by the genome of the cells of the BCG strain of *Mycobacterium bovis*.
4. The method of claim 1, wherein the testing of the population of cells from the subject for the presence in the subject of CD4 T lymphocytes that respond to MTBN4 comprises contacting CD4 T lymphocytes from the subject with antigen presenting cells (APC) and MTBN4 or one or more antigenic fragments thereof.
5. The method of claim 1, wherein the testing of the population of cells from the subject for the presence in the subject of CD4 T lymphocytes that respond to MTBN4 comprises testing for cytokine production.
6. The method of claim 5, wherein the cytokine meas-

ured is IFN $\gamma$ .

7. The method of claim 1, wherein testing a population of cells from a subject for the presence of CD4 T lymphocytes that respond to MTBN4 comprises:

(a) contacting CD4 T lymphocytes with antigen presenting cells (APC) in the presence of MTBN4 or one or more antigenic fragments thereof, wherein said CD4 T lymphocytes are from a population of cells from a subject, and wherein said APC express at least one major histocompatibility complex (MHC) class II molecule expressed by said subject; and  
(b) determining the ability of said CD4 T lymphocytes to respond to MTBN4 or one or more antigenic fragments thereof.

8. The method of claim 2, wherein testing for the presence in the subject of B lymphocytes that produce antibodies that bind to MTBN4, comprises:

(a) contacting the bodily fluid from the subject with MTBN4 or one or more antigenic fragments thereof; and  
(b) testing for binding of antibody in the body fluid to MTBN4, or the one or more antigenic fragments thereof.

9. The method of claim 8, wherein the bodily fluid is blood.

10. The method of claim 8, wherein the bodily fluid is plasma or serum.

11. A composition comprising at least two polypeptides of the *M. tuberculosis* complex, said at least two polypeptides consisting of the MTBN4 sequence, as depicted in Figure 1, and at least one other polypeptide of the *M. tuberculosis* complex, which is not encoded by the genome of the cells of BCG strain of *M. bovis*.

12. A vector comprising:

(a) the DNA molecule encoding the polypeptide MTBN4, as depicted in Figure 1; and  
(b) transcriptional and translational regulatory sequences linked to said DNA sequence, said regulatory sequences allowing for expression of the polypeptide encoded by said DNA sequence in a cell,

for use as a diagnostic.

13. The use of a polypeptide comprising the MTBN4 sequence, as depicted in Figure 1, a composition as defined in claim 11, or a vector as defined in claim

12, for the manufacture of a medicament for diagnosing exposure of a subject to *M. tuberculosis*.

## 5 Patentansprüche

1. Ein *in vitro*-Verfahren zur Diagnose, welches zwischen der Exposition eines Subjekts an *Mycobacterium tuberculosis* (*M. tuberculosis*) und der Exposition eines Subjekts an den Bacille Calmette Guerin-Stamm von *Mycobacterium bovis* (BCG) unterscheidet, wobei das Verfahren das Testen einer Population von Zellen aus einem Subjekt auf das Vorliegen von CD4 T-Lymphozyten, die auf MTBN4, wie es in Figur 1 dargestellt ist, ansprechen, umfasst, wobei das Vorliegen von CD4 T-Lymphozyten, die auf MTBN4 ansprechen, anzeigt, dass das Subjekt an *M. tuberculosis* und nicht an BCG ohne Exposition an *M. tuberculosis* exportiert wurde.

2. Ein *in vitro*-Verfahren zur Diagnose, welches zwischen der Exposition eines Subjekts an *M. tuberculosis* und der Exposition eines Subjekts an BCG unterscheidet, wobei das Verfahren umfasst: das Testen eines Subjekts auf das Vorliegen von B-Lymphozyten, die Antikörper produzieren, die an MTBN4 binden, wobei das Testen mit einer Körperflüssigkeit aus dem Subjekt durchgeführt wird, wobei das Vorliegen in dem Subjekt von B-Lymphozyten, die Antikörper produzieren, die an MTBN4 binden, anzeigt, dass das Subjekt durch Exposition an *M. tuberculosis* und nicht an BCG ohne Exposition an *M. tuberculosis* infiziert wurde.

3. Ein Verfahren wie in Anspruch 1 oder Anspruch 2 beansprucht, wobei das Polypeptid in einer Zusammensetzung vorliegt, die wenigstens ein anderes Polypeptid des *M. tuberculosis*-Komplexes umfasst, wobei das wenigstens eine andere Polypeptid nicht von dem Genom der Zellen des BCG-Stamms von *Mycobacterium bovis* codiert wird.

4. Das Verfahren nach Anspruch 1, wobei das Testen der Population von Zellen aus dem Subjekt auf das Vorliegen in dem Subjekt von CD4 T-Lymphozyten, die auf MTBN4 ansprechen, das Inkontaktbringen von CD4 T-Lymphozyten aus dem Subjekt mit Antigen präsentierenden Zellen (APC) und MTBN4 oder einem oder mehreren antigenen Fragmenten davon umfasst.

5. Das Verfahren nach Anspruch 1, wobei das Testen der Population von Zellen aus dem Subjekt auf das Vorliegen in dem Subjekt von CD4 T-Lymphozyten, die auf MTBN4 ansprechen, das Testen auf eine Cytokinproduktion umfasst.

6. Das Verfahren nach Anspruch 5, wobei das gemess-

sene Cytokin IFN $\gamma$  ist.

7. Das Verfahren nach Anspruch 1, wobei das Testen einer Population von Zellen aus einem Subjekt auf das Vorliegen von CD4 T-Lymphozyten, die auf MTBN4 ansprechen, umfasst:

(a) das Inkontaktbringen von CD4 T-Lymphozyten mit Antigen präsentierenden Zellen (APC) in der Gegenwart von MTBN4 oder einem oder mehreren antigenen Fragmenten davon, wobei die CD4 T-Lymphozyten aus einer Population von Zellen aus einem Subjekt stammen und wobei die APC wenigstens ein Haupthistokompatibilitätskomplex (MHC) Klasse II-Molekül exprimieren, das von dem Subjekt exprimiert wird; und  
(b) das Bestimmen der Fähigkeit der CD4 T-Lymphozyten, auf MTBN4 oder eines oder mehrere antigene Fragmente davon anzusprechen.

8. Das Verfahren nach Anspruch 2, wobei das Testen auf das Vorliegen in dem Subjekt von B-Lymphozyten, die Antikörper produzieren, die an MTBN4 binden, umfasst:

(a) das Inkontaktbringen der Körperflüssigkeit aus dem Subjekt mit MTBN4 oder einem oder mehreren antigenen Fragmenten davon; und  
(b) das Testen auf eine Bindung von Antikörpern in der Körperflüssigkeit an MTBN4 oder das eine oder die mehreren Fragmente davon.

9. Das Verfahren nach Anspruch 8, wobei die Körperflüssigkeit Blut ist.

10. Das Verfahren nach Anspruch 8, wobei die Körperflüssigkeit Plasma oder Serum ist.

11. Eine Zusammensetzung, welche wenigstens zwei Polypeptide des *M. tuberculosis*-Komplexes umfasst, wobei die wenigstens zwei Polypeptide aus der MTBN4-Sequenz, wie sie in Figur 1 dargestellt ist, und wenigstens einem anderen Polypeptid des *M. tuberculosis*-Komplexes, welches nicht von dem Genom der Zellen des BCG-Stamms von *M. bovis* codiert wird, bestehen.

12. Ein Vektor, welcher umfasst:

(a) das DNA-Molekül, welches das Polypeptid MTBN4, wie es in Figur 1 dargestellt ist, codiert; und  
(b) transkriptionale und translationale regulatorische Sequenzen, die mit der DNA-Sequenz verknüpft sind, wobei die regulatorischen Sequenzen eine Expression des Polypeptids, das

von der DNA-Sequenz codiert wird, in einer Zelle erlauben,

zur Verwendung als ein Diagnostikum.

13. Die Verwendung eines Polypeptids, welches die MTBN4-Sequenz, wie sie in Figur 1 dargestellt wird, umfasst, einer Zusammensetzung, wie sie in Anspruch 11 definiert wird, oder eines Vektors, wie er in Anspruch 12 definiert wird, zur Herstellung eines Medikaments zum Diagnostizieren der Exposition eines Subjekts an *M. tuberculosis*.

## 15 Revendications

1. Procédé de diagnostic *in vitro* qui fait une distinction entre l'exposition d'un sujet à *Mycobacterium tuberculosis* (*M. tuberculosis*) et l'exposition d'un sujet à la souche du Bacille de Calmette Guérin de *Mycobacterium bovis* (BCG), le procédé comprenant l'analyse d'une population de cellules provenant d'un sujet en ce qui concerne la présence de lymphocytes T CD4 répondant à MTBN4, comme décrit dans la Figure 1, analyse selon laquelle la présence de lymphocytes T CD4 répondant à MTBN4 indique que le sujet a été exposé à *M. tuberculosis* et pas au BCG sans exposition à *M. tuberculosis*.

2. Procédé de diagnostic *in vitro* qui fait une distinction entre l'exposition d'un sujet à *M. tuberculosis* et l'exposition d'un sujet au BCG, le procédé comprenant : l'analyse d'un sujet en ce qui concerne la présence de lymphocytes B qui produisent des anticorps se liant à MTBN4, l'analyse étant effectuée sur un fluide corporel provenant du sujet, analyse selon laquelle la présence chez le sujet de lymphocytes B qui produisent des anticorps se liant à MTBN4 indiquent que le sujet a été infecté par une exposition à *M. tuberculosis* et pas au BCG sans exposition à *M. tuberculosis*.

3. Procédé selon la revendication 1 ou la revendication 2, dans lequel ledit polypeptide est présent dans une composition comprenant au moins un autre polypeptide du complexe de *M. tuberculosis*, ledit au moins un autre polypeptide n'étant pas codé par le génome des cellules de la souche du BCG de *Mycobacterium bovis*.

4. Procédé selon la revendication 1, dans lequel l'analyse de la population de cellules provenant du sujet en ce qui concerne la présence chez le sujet de lymphocytes T CD4 répondant à MTBN4 comprend la mise en contact de lymphocytes T CD4 provenant du sujet avec des cellules présentatrices d'antigène (APC) et MTBN4 ou un ou plusieurs fragments antigéniques de celui-ci.

5. Procédé selon la revendication 1, dans lequel l'analyse de la population de cellules provenant du sujet en ce qui concerne la présence chez le sujet de lymphocytes T CD4 répondant à MTBN4 comprend une analyse de la production de cytokine. 5
6. Procédé selon la revendication 5, dans lequel la cytokine mesurée est IFN- $\gamma$ .
7. Procédé selon la revendication 1, dans lequel une analyse d'une population de cellules provenant d'un sujet en ce qui concerne la présence de lymphocytes T CD4 répondant à MTBN4 comprend : 10
- (a) la mise en contact de lymphocytes T CD4 avec des cellules présentatrices d'antigène (APC) en présence de MTBN4 ou un ou plusieurs fragments antigéniques de celui-ci, dans laquelle lesdits lymphocytes T CD4 proviennent d'une population de cellules provenant d'un sujet, et dans laquelle lesdites APC expriment au moins une molécule de classe II du complexe majeur d'histocompatibilité (MHC) exprimé par ledit sujet ; et 20
- (b) la détermination de la capacité desdits lymphocytes T CD4 à répondre au MTBN4 ou à un ou plusieurs fragments antigéniques de celui-ci. 25
8. Procédé selon la revendication 2, dans lequel l'analyse en ce qui concerne la présence chez le sujet de lymphocytes B qui produisent des anticorps se liant à MTBN4, comprend : 30
- (a) la mise en contact du fluide corporel provenant du sujet avec MTBN4 ou un ou plusieurs fragments antigéniques de celui-ci ; et 35
- (b) l'analyse de la liaison de l'anticorps du fluide corporel à MTBN4, ou à un ou plusieurs fragments antigéniques de celui-ci. 40
9. Procédé selon la revendication 8, dans lequel le fluide corporel est du sang.
10. Procédé selon la revendication 8, dans lequel le fluide corporel est du plasma ou du sérum. 45
11. Composition comprenant au moins deux polypeptides du complexe de *M. tuberculosis*, lesdits au moins deux polypeptides consistant en la séquence de MTBN4, comme décrit dans la Figure 1, et au moins un autre polypeptide du complexe de *M. tuberculosis*, qui n'est pas codé par le génome des cellules de la souche du BCG de *M. bovis*. 50
12. Vecteur comprenant ; 55
- (a) la molécule d'ADN codant pour le polypeptide MTBN4, comme décrit dans la Figure 1 ; et
- (b) les séquences de régulation de transcription et de traduction liées à ladite séquence d'ADN, lesdites séquences de régulation permettant l'expression du polypeptide codé par ladite séquence d'ADN dans une cellule,
- pour une utilisation en tant que diagnostic.
13. Utilisation d'un polypeptide comprenant la séquence MTBN4, comme décrit dans la Figure 1, une composition telle que définie dans la revendication 11, ou un vecteur tel que défini dans la revendication 12, pour la préparation d'un médicament pour diagnostiquer l'exposition d'un sujet à *M. tuberculosis*.

FIG. 1

MTBN1

MTAEPEVRTLREVVLDQLGTAESRAYKMWLPPLTNPVPLNELIARDRRQPLRFALGIMDE  
 PRRHLQDVWGVVDVSGAGGNIGIGGAPQTGKSTLLQTMVMSAAATHSPRNVOFYCIDLGGG  
 GLIYLENLPHVGGVANRSEPDKVN RVVAEMQAVMRQRETTFKEHRVGSIGMYRQLRDDPS  
 QPVASDPYGDVFLI IDGWPGFVGEFPDLEGQVQDLAAQGLAFGVHVI I STPRWTELKSRV  
 RDYLGTKIEFRLGDVNETQIDRITREIPANRPGRAVSMKHHLMIGVPRFDGVHSADNLV  
 EAITAGVTQIASQHTEQAPPVRLPERIHLHELDPNPPGPESDYRTRWEIPIGLRETDLT  
 PAHCHMHTNPHLLIFGAAKSGKTTIAHAIARAI CARNSPQQVRFMLADYRSGLLDAVPDT  
 HLLGAGAINRNSASLDEAVQALAVNLKRLPPTDLTTAQLRSRSWWSGFDVLLVDDWHM  
 IVGAAGMPPMAPLAPLLPAAADIGLHIIVTCQMSQAYKATMDKFFVGAAFGSGAPT MFLS  
 GEKQEFPSSEFKVRRPPGQAFVSPDGKEVIQAPYIEPPEEVFAAPPSAG\*

MTBN2

MEKMSHDP I AADI GTQVSDNALHGVTAGSTALTSVTGLVPAGADEVSAQAATAFTSEGIQ  
 LLASNASAQDQLHRAGEAVQDVARTYSQIDDGAAGVFAE\*

MTBN3

MLWHAMPPELNTARLMAGAGPAPMLAAAAGWQTL SAALDAQAVELTARLNSLGEAWTGGG  
 SDKALAAATPMVVWLQTASTQAKTRAMQATAQAAAAYTQAMATTPSLPEIAANHITQAVLT  
 ATNFFGINTIPIALTEMDYFIRMWNQAALAMEVYQAEAVNTLFEKLEPMASILDPGASQ  
 STTNPIFGMPSPGSSTPVGQLPPAATQTLGQLGEMSGPMQOLTQPLQOVTSLFSQVGGTG  
 GGNPADEEAAQMGLLGTSPLSNHPLAGGSGPSAGAGLLRAESLPGAGGSLTRTPLMSQLI  
 EKPVAPSVMPAAAAGSSATGGAAPVGAGAMGQGAQSGGSTRPGLVAPAPLAQEREDEDED  
 DWDEEDDW\*

MTBN4

MAEMKTDAAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVVRFQE  
 AANKQKQELDEI STNIRQAGVQYSRADEEQQALSSQMGF\*

MTBN5

MAADYDKLFRPHEGMEAPDDMAAQPFDPSPASFPPAPASANLPKPNGQTPPPTSDDLSE  
 FVSAPPPPPPPPPPPPTPMPIAAGEPPSPEPAASKPPTPPMPIAGPEPAPPKPTPPMP  
 IAGPEPAPPKPTPPMPIAGPAPTPTESQLAPPRPPTPQTPTGAPQQPES PAPHVPSHGP  
 HQPRRTAPAPPWAKMPIGEPSPAPSRPSASPAEPPTRPAPQHSRRARRGHRYRTDTERNV  
 GKVATGPSIQARLRAEEASGAQLAPGTEPSPAPLQGQPRSYLAPPTRPAPTEPPPSPSQR  
 NSGRRRAERRVHPDLAAQHAAAQPDSTATTGGRRRKRAAPDLDATQKSLRPAAKGPKVK  
 KVKPKPKATKPPKVVSRGWRHWHVHALTRINLGLSPDEKYELDLHARVRRNPRGSYQIA  
 VVGLKGGAGKTTLTAALGSTLAQVRADRI LALDADPGAGNLADRVGRQSGATIADVLAEK  
 ELSHYNDIRAHTSVNAVNLVLPAPPEYSSAQRALSDADWHFIADPASRFYNLVLADCGAG  
 FFDPLTRGVLSTVSGVVVASV SIDGAQQASVALDWLRNNGYQDLASRACVVINHIMPGE  
 PNVAVKDLVRHFEQQVQGRVVVMPWDRHIAAGTEI SLDLLDPIYKRKVL ELAAALSDDF  
 ERAGR\*



FIG. 2

mtbn1

```

1   atgactgctg aaccggaagt acggacgctg cgcgaggttg tgctggacca
51  gctcggcact gctgaatcgc gtgcgtacaa gatgtggctg ccgcccgtga
101 ccaatccggt cccgctcaac gagctcatcg cccgtgatcg gcgacaaccc
151 ctgcgatttg ccctggggat catggatgaa ccgcccgcgc atctacagga
201 tgtgtggggc gtagacgttt ccggggccgg cggcaacatc ggtattgggg
251 gcgcacctca aaccgggaag tcgacgctac tgcagacgat ggtgatgtcg
301 gccgccgcca cacactcacc gcgcaacggt cagttctatt gcatcgacct
351 aggtggcggc gggctgatct atctcgaaaa ccttccacac gtcgggtggg
401 tagccaatcg gtccgagccc gacaaggctc accgggtggt cgcagagatg
451 caagccgtca tgcggcaacg ggaaaccacc ttcaaggaac accgagtggt
501 ctcgatcggg atgtaccggc agctgcgtga cgatccaagt caaccctgtg
551 cgtccgatcc atacggcgac gtctttctga tcatcgacgg atggcccggg
601 tttgtcggcg agttccccga ccttgagggg caggttcaag atctggccgc
651 ccaggggctg gcgttcggcg tccacgtcat catctccacg ccacgctgga
701 cagagctgaa gtcgcgtggt cgcgactacc tcggcaccaa gatcgagttc
751 cggcttggtg acgtcaatga aaccagatc gaccggatta cccgcgagat
801 cccggcgaat cgtccgggtc gggcagtgct gatggaaaag caccatctga
851 tgatcggcgt gccacgggtc gacggcgtgc acagcgcga taacctggtg
901 gaggcgatca ccgcccgggt gacgcagatc gcttcccagc acaccgaaca
951 ggcacctccg gtgcccgggtc tgcccggagcg tatccacctg cacgaactcg
1001 acccgaaccc gcccccgggtc gagtccgact accgcactcg ctgggagatt
1051 ccgatcggct tgcgcgagac ggacctgacg ccggctcact gccacatgca
1101 cacgaaccgg cacctactga tcttcgggtg gcccaaatcg ggcaagacga
1151 ccattgcccc cgcgatcggc cgcgccattt gtgcccgaaa cagtcccag
1201 caggtgaggc tcatgctcgc ggactaccgc tcgggcctgc tggacgaggg
1251 gccggacacc catctgctgg gcgccggcgc gatcaaccgc aacagcgcgt
1301 cgctagacga ggccgttcaa gcaactggcg tcaacctgaa gaagcgggtg
1351 ccgccgaccg acctgacgac ggcgcagcta cgctcgcgtt cgtgggtggg
1401 cggatttgac gtcgtgcttc tggtcgacga ttggcacatg atcgtgggtg
1451 ccgccggggg gatgccgccc atggcaccgc tggcccgtt attgccggcg
1501 gcggcagata tcgggttgca catcattgtc acctgtcaga tgagccaggc
1551 ttacaaggca accatggaca agttcgtcgg cgcgcattc gggtcggggc
1601 ctccgacaat gttcctttcg ggcgagaagc aggaattccc atccagtgag
1651 ttcaaggctc agcggcgccc ccctggccag gcatttctcg tctcggcaga
1701 cggcaaagag gtcattccagg cccctacat cgagcctcca gaagaagtgt
1751 tcgcagcacc cccaagcgc ggttaa

```

mtbn2

```

1   atggaaaaaa tgtcacatga tccgatcgct gccgacattg gcacgcaagt
51  gagcgacaac gctctgcacg gcgtgacggc cggctcgacg gcgctgacgt
101 cggtgaccgg gctggttccc gcggggggcc atgaggtctc cgccaagcg
151 gcgacggcgt tcacatcgga gggcatccaa ttgctggctt ccaatgcatc
201 ggcccaagac cagctccacc gtgcggggcg agcgggtccag gacgtcggcc
251 gcacctattc gcaaatcgac gacggcggcc cggcgtctt cgcctaatag

```

mtbn3

```

1   atgctgtggc acgcaatgcc accggageta aataccgcac ggctgatggc
51  cggcgggggt ccggctccaa tgcttgccgg gcccgcgagg tggcagacgc
101 tttcggcggc tctggacgct caggccgtcg agttgaccgc gcgcctgaac

```

FIG. 2 (continued)

```

151 tctctgggag aagcctggac tggaggtggc agcgacaagg cgcttgccggc
201 tgcaacgccg atggtggtct ggctacaaac cgcgtcaaca caggccaaga
251 cccgtgcgat gcaggcgacg gcgcaagccg cggcatacac ccaggccatg
301 gccacgacgc cgtcgtctgcc ggagatcgcc gccaaccaca tcaccaggc
351 cgtccttacg gccaccaact tcttcggtat caacacgatc ccgatcgcgt
401 tgaccgagat ggattatctt atccgtatgt ggaaccaggc agccctggca
451 atggaggtct accaggccga gaccgcggtt aacacgcttt tcgagaagct
501 cgagccgatg gcgtcgatcc ttgatcccgg cgcgagccag agcacgacga
551 acccgatcct cggaatgccc tcccctggca gctcaacacc ggttggccag
601 ttgccgccgg cggctacceca gaccctcggc caactgggtg agatgagcgg
651 cccgatgcag cagctgaccc agccgctgca gcaggtgacg tcgttgttca
701 gccaggtggg cggcaccggc ggcggcaacc cagccgacga ggaagccgcg
751 cagatgggcc tgctcggcac cagtccgctg tcgaaccatc cgctggctgg
801 tggatcagge cccagcgagg gcgcgggctt gctgcgcgcg gactcgctac
851 ctggcgcagg tgggtcgttg acccgcacgc cgtgatgtc tcagctgatc
901 gaaaagccgg ttgccccctc ggtgatgccg gcggctgctg ccggatcgtc
951 ggcgacgggt ggcgcgcctc cgggtgggtg gggagcgatg ggccaggggtg
1001 cgcaatccgg cggctccacc aggcggggtc tggtcgcgcc ggcaccgctc
1051 gcgcaggagc gtgaagaaga cgacgaggac gactgggacg aagaggacga
1101 ctggtga

```

mtbn4

```

1 atggcagaga tgaagaccga tgccgctacc ctgcgcgagg aggcaggtaa
51 tttcgagcgg atctccggcg acctgaaaac ccagatcgac caggtggagt
101 cgacggcagg ttcggtgacg ggcagtgcc gcggcgcggc ggggacggcc
151 gcccaggccg cggtggtgag cttccaagaa gcagccaata agcagaagca
201 ggaactcgac gagatctcga cgaatattcg tcaggccggc gtccaatact
251 cgagggccga cgaggagcag cagcaggcgc tgtcctcgca aatgggcttc
301 tga

```

mtbn5

```

1 atggcggccg actacgacaa gctcttcggg ccgacgaag gtatggaagc
51 tccgacgat atggcagcgc agccgttctt cgaccccagt gtttcgcttc
101 cgccggcgcc cgcacggca aacctaccga agcccaacgg ccagactccg
151 cccccgacgt ccgacgacct gtcggagcgg ttcgtgctcg ccccgccgcc
201 gccaccccca cccccacctc cgcctccgcc aactccgatg ccgatcgccg
251 caggagagcc gccctcgccg gaaccggccg catctaaacc acccacacc
301 cccatgcca tcgcccggacc cgaaccggcc ccacccaac caccacacc
351 cccatgccc atcgccggac ccgaaccggc cccacccaac caccacacc
401 ctccgatgcc catcgccgga cctgcaccca cccaaccga atcccagttg
451 gcgcccccca gaccaccgac accacaaaac ccaaccggag cgccgcagca
501 accggaatca ccggcgcccc acgtaccctc gcacgggcca catcaacccc
551 ggcgcaccgc accagcaccg ccttgggcaa agatgccaat cggcgaacc
601 ccgcccgtc cgtccagacc gtctgcgtcc ccggccgaac caccgaccg
651 gcctgcccc caacactccc gacgtgcgcg ccggggtcac cgctatcgca
701 cagacaccga acgaaacgtc gggaaaggtg caactggtcc atccatccag
751 gcgcggctgc gggcagagga agcatccggc gcgcagctcg ccccggaac
801 ggagccctcg ccagcgcgct tgggccaacc gagatcgtat ctggctccgc
851 ccaccgcccc cgcgcccgaca gaacctcccc ccagcccctc gccgcagcgc
901 aactccggtc ggcgtgcccga gcgacgcgct caccgccatt tagccgcca

```

FIG. 2 (continued)

```

951  acatgccgcg  gcgcaacctg  attcaattac  ggccgcaacc  actggcggtc
1001 gtcgccgcaa  gcgtgcagcg  cgggatctcg  acgcgacaca  gaaatcctta
1051 aggccggcgg  ccaagggggc  gaaggtgaag  aaggtgaagc  cccagaaacc
1101 gaaggccacg  aagccgcca  aagtgggtgc  gcagcgcggc  tggcgacatt
1151 ggggtcatgc  gttgacgcga  atcaacctgg  gcctgtcacc  cgacgagaag
1201 tacgagctgg  acctgcacgc  tcgagtccgc  cgcaatcccc  gcgggtcgta
1251 tcagatcgcc  gtcgtcggtc  tcaaaggtgg  ggctggcaaa  accacgctga
1301 cagcagcggt  ggggtcgacg  ttggctcagg  tgcgggccga  ccggatcctg
1351 gctctagacg  cggatccagg  cgccggaaac  ctcccgatc  gggtagggcg
1401 acaatcgggc  gcgaccatcg  ctgatgtgct  tgcagaaaaa  gagctgtcgc
1451 actacaacga  catccgcgca  cacactagcg  tcaatgcggt  caatctggaa
1501 gtgctgccgg  caccggaata  cagctcggcg  cagcgcgcgc  tcagcgcgc
1551 cgactggcat  ttcacgcgcg  atcctgcgct  gaggttttac  aacctcgtct
1601 tggctgattg  tggggccggc  ttcttcgacc  cgctgacctg  cggcgtgctg
1651 tccacgggtg  ccgggtgctg  ggtcgtggca  agtgtctcaa  tcgacggcgc
1701 acaacaggcg  tcggtcgcgt  tggactgggt  gcgcaacaac  ggttaccag
1751 atttggcgag  ccgcgcagc  gtggctatca  atcacatcat  gccgggagaa
1801 cccaatgtcg  cagttaaaga  cctgggtcgg  catttcgaac  agcaagtcca
1851 acccggcggg  gtcgtggtca  tgccgtggga  caggcacatt  gcggccggaa
1901 ccgagatttc  actcgacttg  ctcgacccta  tctacaagcg  caaggctctc
1951 gaattggccg  cagcgcctatc  cgacgatttc  gagagggctg  gacgtcgttg
2001  a

```

mtbn6

```

1  ttgagcgcac  ctgctgttgc  tgctggctct  accgccgcg  gggcaaccgc
51  tgcgcggcct  gccaccacc  gggtgacgat  cctgaccgg  agacggatga
101  ccgatttgg  actgccagcg  gcggtgccga  tggaaactta  tattgacgac
151  accgtcgcgg  tgctttccga  ggtgttgaa  gacacgcgg  ctgatgtact
201  cggcggcttc  gactttaccg  cgcaaggcgt  gtgggcgctc  gctcgtccc
251  gatcgcgcgc  gctgaagctc  gaccagtcac  tcgatgacgc  cggggtggtc
301  gacgggtcac  tgctgactct  ggtgtcagtc  agtcgcaccg  agcgtaccg
351  accgttggtc  gaggatgtca  tcgacgcgat  cgccgtgctt  gacgagtcac
401  ctgagttcga  ccgcacggca  ttgaatcgct  ttgtgggggc  ggcgatccc
451  cttttgaccg  cgcccgtcat  cgggatggcg  atgcgggcgt  ggtgggaaac
501  tgggcgtagc  ttgtgggtgg  cgttggcgat  tggcatcctg  gggatcgctg
551  tgctggtagg  cagcttcgtc  gcgaacaggt  tctaccagag  cggccacctg
601  gccgagtgcc  tactggtcac  gacgtatctg  ctgatcgcaa  ccgccgcagc
651  gctggccgctg  ccgttgccgc  gcggggtcaa  ctcgttgggg  gcgccacaag
701  ttgcccggcg  cgctacggcc  gtgctgtttt  tgacctgat  gacgcggggc
751  ggcctcggga  agcgtcatga  gttggcgtcg  tttgccgtga  tcaccgctat
801  cgcggtcac  gcggccggcg  ctgcctcgg  ctatggatac  caggactggg
851  tccccgcggg  ggggatcgca  ttcgggctgt  tcatgtgac  gaatgcggcc
901  aagctgaccg  tcgcggtcgc  gcggatcgcg  ctgccgccga  ttccgggtacc
951  cggcgaaacc  gtggacaacg  aggagtgtct  cgatcccgtc  gcgacccgg
1001  aggctaccag  cgaagaaacc  ccgacctggc  aggccatcat  cgctcgggtg
1051  cccgcgtccg  cggtcggct  caccgagcgc  agcaaactgg  ccaagcaact
1101  tctgatcgga  tacgtcacgt  cgggcaccct  gattctggct  gccggtgcca
1151  tcgcggtcgt  ggtgcgcggg  cacttctttg  tacacagcct  ggtggtcgcg
1201  ggtttgatca  cgaccgtctg  cggatttcgc  tcgcggttt  acgccgagcg
1251  ctggtgtgcg  tgggcgttgc  tggcggcgac  ggtcgcgatt  ccgacgggtc
1301  tgacggccaa  actcatcatc  tggatcccgc  actatgcctg  gctgttgttg

```

FIG. 2 (continued)

1351 agcgtctacc tcacggtagc cctgggttgcg ctcgtgggtgg tcggggtcgat  
 1401 ggctcacgtc cggcgcggtt caccggtcgt aaaacgaact ctggaattga  
 1451 tcgacggcgc catgatcgct gccatcattc ccatgctgct gtggatcacc  
 1501 ggggtgtacg acacgggtccg caatatccgg ttctga

mtbn7

1 atggctgaac cgttggccgt cgatcccacc ggcttgagcg cagcggccgc  
 51 gaaattggcc ggcctcggtt ttccgcagcc tccggcgccc atcgcggtca  
 101 gcggaacgga ttcgggtgta gcagcaatca acgagaccat gccaaagcatc  
 151 gaatcgctgg tcagtgacgg gctgcccggc gtgaaagccg ccctgactcg  
 201 aacagcatcc aacatgaacg cggcggcgga cgtctatgcg aagaccgatc  
 251 agtcactggg aaccagtttg agccagtatg cattcggctc gtcggggcga  
 301 ggcttggtg gcgtcgccctc ggtcgggtgg cagccaagtc aggctacca  
 351 gctgctgagc acaccggtgt cacagggtcac gacccagctc ggcgagacgg  
 401 ccgctgagct ggcaccccgt gttgttgca cgggtgccga actcgttcag  
 451 ctggctccgc acgcccgttca gatgtcgcaa aacgcacccc ccatcgctca  
 501 gacgatcagt caaacccccc aacaggccgc ccagagcgcg cagggcggca  
 551 gggcccaat gcccgcacag cttgccagcg ctgaaaaacc ggccaccgag  
 601 caagcggagc cgggtccacga agtgacaaac gacgatcagg gcgaccaggg  
 651 cgacgtgcag ccggccgagg tcgttgccgc ggcacgtgac gaaggcgccg  
 701 gcgcatcacc gggccagcag cccggcgggg gcgttcccgc gcaagccatg  
 751 gataccggag ccggtgcccg cccagcggcg agtccgctgg cggccccctg  
 801 cgatccgctc actccggcac cctcaacaac cacaacgttg tag

mtbn8

1 atgagtatta ccaggccgac gggcagctat gccagacaga tgctggatcc  
 51 gggcggctgg gtggaagccg atgaagacac tttctatgac cggggcccagg  
 101 aatatagcca ggttttgcaa agggtcaccg atgtattgga cacctgccgc  
 151 cagcagaaag gccacgtctt cgaaggcggc ctatggtccg gcggcgccgc  
 201 caatgctgcc aacggcgccc tgggtgcaaa catcaatcaa ttgatgacgc  
 251 tgcaggatta tctcgccacg gtgattacct ggcacaggca tattgcccggg  
 301 ttgattgagc aagctaaatc cgatatcggc aataatgtgg atggcgctca  
 351 acgggagatc gatatcctgg agaatgacc tagcctggat gctgatgagc  
 401 gccataccgc catcaattca ttggtcacgg cgacgcatgg ggccaatgtc  
 451 agtctggtcg ccgagaccgc tgagcgggtg ctggaatcca agaattggaa  
 501 acctccgaag aacgcactcg aggatttgct tcagcagaag tcgccgccac  
 551 ccccagacgt gcctaccctg gtcgtgccat ccccgggcac accgggcaca  
 601 ccgggaacc ccatcaccgc gggaaaccgc atcaccgccg gaacccaat  
 651 cacaccatc ccgggagcgc cggtaactcc gatcacacca acgcccggca  
 701 ctcccgtcac gccggtgacc ccgggcaagc cggtcacccc ggtgaccccg  
 751 gtcaaaccgg gcacaccagg cgagccaacc ccgatcacgc cggtcacccc  
 801 cccggtcgcc ccggccacac cggcaacccc ggccacgccc gttaccccag  
 851 ctcccgtccc acaccgcag ccggctccgg caccggcgcc atcgctggg  
 901 ccccagccgg ttacaccggc cactcccggg ccgtctggtc cagcaacacc  
 951 gggcacccca gggggcgagc cggcgcgcga cgtcaaacc gcggcgttgg  
 1001 cggagcaacc tgggtgtgccc ggccagcatg cgggcggggg gacgcagtcg  
 1051 gggcctgccc atgcggacga atccgcccg tccggtgacgc cggctgcggc  
 1101 gtccggtgtc ccgggcccac gggcggcggc cgccgcgcgc agcggtagccg  
 1151 ccgtgggagc gggcgcgcgt tcgagcgtgg gtacggccgc ggcctcgggc  
 1201 gcgggggtcgc atgctgccac tgggcccggc cgggtggcta cctcggacaa

FIG. 2 (continued)

```

1251 ggcggcggca ccgagcacgc gggcggcctc ggcgcggacg gcacctcctg
1301 cccgcccgcc gtcgaccgat cacatcgaca aaccgatcg cagcgagtct
1351 gcagatgacg gtacgccggt gtcgatgatc ccggtgtcgg cggctcgggc
1401 ggcacgcgac gccgccactg cagctgccag cgcccgccag cgtggccgcg
1451 gtgatgcgct gcggttggcg cgacgcacgc cggcggcgcct caacgcgtcc
1501 gacaacaacg cgggcgacta cgggttcttc tggatcaccg cggtgaccac
1551 cgacggttcc atcgtcgtgg ccaacagcta tgggctggcc tacatacccg
1601 acgggatgga attgccgaat aagggtgtact tggccagcgc ggatcacgca
1651 atcccggttg acgaaattgc acgctgtgcc acctaccggg ttttggccgt
1701 gcaagcctgg gcggctttcc acgacatgac gctgcgggcg gtgatcggta
1751 ccgcgaggca gttggccagt tcggatcccg gtgtggccaa gattgtgctg
1801 gagccagatg acattccgga gagcggcaaa atgacgggcc ggtcgcggct
1851 ggaggtcgtc gaccctcgg cgccggctca gctggccgac actaccgatc
1901 agcgtttgct cgacttggtg ccgccggcgc cggtggatgt caatccaccg
1951 ggcgatgagc ggcacatgct gtggttcgag ctgatgaagc ccatgaccag
2001 caccgctacc ggccgcgagg ccgctcatct gcgggcgttc cgggcctacg
2051 ctgcccactc acaggagatt gccctgcacc aagcgcacac tgcgactgac
2101 gcggccgtcc agcgtgtggc cgtcgcggac tggctgtact ggcaatacgt
2151 caccgggttg ctcgaccggg ccctggccgc cgcatgctga

```




Fig.3

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- US 796792 A [0031] [0033]

**Non-patent literature cited in the description**

- **COLE et al.** *Nature*, 1998, vol. 393, 537-544 [0029]
- **MAHAIRAS et al.** *J. Bacteriol.*, 1996, vol. 178, 1274-1282 [0030]

专利名称(译)	由结核分枝杆菌而不是BCG表达的蛋白质及其作为诊断试剂和疫苗的用途		
公开(公告)号	<a href="#">EP1214088A4</a>	公开(公告)日	2003-06-11
申请号	EP2000928851	申请日	2000-05-04
[标]申请(专利权)人(译)	公共卫生RES INST纽约市的		
[标]发明人	GENNARO MARIA L		
发明人	GENNARO, MARIA, L.		
IPC分类号	G01N33/53 A61K31/711 A61K38/00 A61K39/00 A61K39/04 A61K48/00 A61P31/04 A61P31/06 C07K14/35 C12N1/15 C12N1/19 C12N1/21 C12N5/10 C12N15/09 C12Q1/02 A61K39/02 C07H21/02 C07H21/04 C07K1/00 C12P21/06 C12N1/00 C12N1/12		
CPC分类号	A61K49/0006 A61K38/00 A61K39/00 A61K39/04 A61K2039/53 C07K14/35 G01N33/5091 G01N33/5695 G01N2333/35 G01N2333/57 G01N2800/26 Y10S435/863		
优先权	60/132505 1999-05-04 US		
其他公开文献	EP1214088A1 EP1214088B1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本发明提供了由存在于结核分枝杆菌基因组中但不存在于BCG基因组中的开放阅读框编码的多肽以及使用这些多肽的诊断和预防方法。